Prion diseases are rare. This page gives the patient numbers that public health bodies publish and says what treatment exists. It does not estimate market size. The figures for a drug developer’s own forecast need a source this page does not use.
How many people have prion disease?
The CDC says about 500 to 600 cases are reported each year in the United States and that the worldwide rate is roughly 1 to 2 deaths per million people per year. The NHS gives a similar figure for sporadic CJD in the United Kingdom, 1 or 2 people per million each year, and lists 131 deaths from sporadic CJD in 2020, with no variant CJD deaths, 6 from familial and similar inherited prion diseases, and 1 from iatrogenic CJD. The NHS page does not give a total case count.
What are the main types?
| Type | Share of cases (CDC) |
|---|---|
| Sporadic | About 85 percent |
| Familial (inherited PRNP mutation) | About 5 to 15 percent |
| Iatrogenic (acquired through healthcare) | Not stated on the page |
Classic CJD usually starts at age 55 or older. Median survival from symptom onset is about 4 to 5 months, according to the CDC. The NHS says most people die within a year of symptoms starting.
What treatment exists?
None that stops progression. The CDC states that care is supportive only, and the NHS says treatment is directed at relieving symptoms and keeping the person comfortable, for example with antidepressants for anxiety and depression and painkillers for pain. Some people need nursing care and help with feeding. Drug trials to date have been small, and the pipeline overview lists the programmes now in trials, none of which has reported efficacy in people.
What is not known?
- How many people are living with a diagnosis at one time. The sources give annual incidence, which is not the same.
- The number of people carrying a pathogenic PRNP variant who have not developed disease. The pages read give no figure, and carrier status is private health information that this site does not estimate.
- Quality of life or cost-of-care data. The sources read do not report them.
Recruitment practicalities are on trial feasibility, engagement with families is on working with patient groups, and background rates are on the epidemiology page. The pharma overview links the rest.